Pacira Pharmaceuticals (PCRX) AI Stock Analysis

• Market Cap: $883.66M
• Dividend Yield: N/A
• Average Volume (3M): 835.58K
• Price to Earnings (P/E): 46.0
• Beta (1Y): 0.87
• Revenue Growth: 3.14%
• EPS Growth: N/A
• Country: US
• Employees: 788
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.70
• Shares Outstanding: 43,021,275
• 10 Day Avg. Volume: 764,339
• 30 Day Avg. Volume: 835,580
• PEG Ratio: 0.03
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 1.24
• P/FCF Ratio: 4.87
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 1.62
• Enterprise Value/Gross Profit: 2.05
• Enterprise Value/Ebitda: 7.86
• 1Y Price Target: $29.71
• Price Target Upside: 44.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: $21.00 ▲(2.24% Upside)

The score is driven primarily by solid financial health and cash flow strength with minimal leverage, supported by a generally positive earnings-call outlook. This is tempered by weak technicals (price below key moving averages with negative MACD) and a relatively high P/E with no dividend support.

Positive Factors

Balance sheet strength

Extremely low leverage (debt/equity ~0.013) gives Pacira durable financial flexibility to fund R&D, advance pipeline assets, pursue partnerships or weather cyclical downturns without relying on dilutive or expensive external financing. This underpins long-term strategic optionality.

Consistent cash generation

Strong cash conversion (OCF/net income 1.32, FCF growth 6.1% TTM, FCF/net income 0.88) provides sustainable internal funding for product development, commercial investment, and $50M share repurchases, reducing reliance on external capital and supporting long-term value creation.

EXPAREL traction and improving margins

Renewed EXPAREL demand (volumes up ~9%) alongside higher non-GAAP gross margins (82% vs 78% prior year) indicates durable product adoption and manufacturing efficiencies. Patent listings and in-licensing (AMT-143) strengthen the product franchise and future organic growth prospects.

Negative Factors

Low net profitability

A net margin near 4.1% limits retained earnings and weakens the company’s ability to self-fund aggressive growth or absorb sustained pricing pressure. Even with solid gross margins, limited bottom-line profitability constrains long-term free cash flow expansion and shareholder returns.

Modest revenue growth trend

TTM revenue growth around 1.5% signals slow top-line momentum despite recent quarterly improvement. Sustained low organic growth raises execution risk for the company’s multi-year ‘5x30’ target, making attainment contingent on successful pipeline launches or market-share gains rather than base business expansion.

Pricing and market-access pressure

Contract-driven GPO discounting is a structural headwind that can erode realized prices and margins over time. With material reliance on EXPAREL sales, sustained pricing pressure and reduced net selling prices amplify revenue volatility and elevate the importance of scale or new differentiated products to protect profitability.

Pacira Pharmaceuticals Business Overview & Revenue Model

Company Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

How the Company Makes Money

Pacira Pharmaceuticals generates revenue primarily through the sales of its flagship product, EXPAREL, which is marketed to hospitals, surgical centers, and healthcare providers. The company also earns revenue from collaborations and partnerships with other pharmaceutical firms, which may include licensing agreements or co-development arrangements for its pipeline products. Additionally, Pacira may benefit from government reimbursements and healthcare insurance payments for its products, which are crucial for driving sales and expanding market access. The company has strategically focused on building relationships with healthcare professionals and institutions to promote the adoption of non-opioid pain management solutions, contributing to its overall revenue growth.

Pacira Pharmaceuticals Financial Statement Overview

Summary

Solid overall fundamentals supported by strong cash generation (FCF growth 6.1% TTM; OCF/NI 1.32) and a very low debt-to-equity ratio (0.013 TTM). Offsetting this, profitability remains modest (net margin 4.13%) and revenue growth is only incremental (1.55% TTM).

Income Statement

Pacira Pharmaceuticals shows a modest revenue growth rate of 1.55% TTM, with a stable gross profit margin of 58.9%. However, the net profit margin is relatively low at 4.13%, indicating limited profitability. The EBIT and EBITDA margins have improved over the previous year, suggesting better operational efficiency.

Balance Sheet

The company has significantly reduced its debt-to-equity ratio to 0.013 TTM, indicating strong financial stability. The return on equity is modest at 3.87%, reflecting moderate profitability. The equity ratio is healthy, showing a solid capital structure.

Cash Flow

Pacira Pharmaceuticals has achieved a free cash flow growth rate of 6.1% TTM, demonstrating strong cash generation capabilities. The operating cash flow to net income ratio is robust at 1.32, indicating efficient cash conversion. The free cash flow to net income ratio is also strong at 0.88.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	716.79M	700.97M	674.98M	666.82M	541.53M	429.65M
Gross Profit	567.46M	530.54M	490.31M	467.53M	401.28M	312.32M
EBITDA	147.82M	29.12M	154.59M	140.38M	113.95M	63.51M
Net Income	21.44M	-99.56M	41.95M	15.91M	41.98M	145.52M
Balance Sheet
Total Assets	1.30B	1.55B	1.57B	1.68B	2.08B	1.27B
Cash, Cash Equivalents and Short-Term Investments	246.33M	484.62M	278.58M	288.65M	656.41M	521.66M
Total Debt	425.31M	638.85M	586.04M	763.39M	1.13B	541.13M
Total Liabilities	570.36M	775.17M	704.26M	906.19M	1.34B	654.83M
Stockholders Equity	727.21M	778.35M	870.13M	775.01M	730.41M	619.69M
Cash Flow
Free Cash Flow	124.20M	178.75M	139.49M	115.20M	79.85M	39.23M
Operating Cash Flow	141.44M	189.39M	154.65M	145.27M	125.72M	77.03M
Investing Cash Flow	79.78M	-83.28M	77.54M	-225.19M	-20.79M	-277.61M
Financing Cash Flow	-319.93M	17.36M	-183.03M	-401.53M	380.69M	222.30M

Pacira Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 20.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Negative. The current price of 20.54 is below the 20-day moving average (MA) of 21.97, below the 50-day MA of 23.76, and below the 200-day MA of 24.26, indicating a bearish trend. The MACD of -1.23 indicates Positive momentum. The RSI at 39.41 is Neutral, neither overbought nor oversold. The STOCH value of 57.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PCRX.

Pacira Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	79 Outperform	$1.22B	11.75	14.84%	―	-0.03%	-27.66%
COLL	72 Outperform	$1.45B	28.58	22.96%	―	26.34%	-32.79%
ANIP	66 Neutral	$1.84B	50.20	7.83%	―	48.87%	―
PCRX	64 Neutral	$883.66M	46.04	2.90%	―	3.14%	―
AVDL	57 Neutral	$2.11B	-3,918.18	-0.32%	―	79.88%	99.60%
SUPN	55 Neutral	$2.76B	-141.31	-1.86%	―	4.54%	-130.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Pacira Pharmaceuticals Corporate Events

Pacira BioSciences adds seasoned leader to board

On January 27, 2026, Pacira BioSciences expanded its Board of Directors from nine to 10 members and appointed veteran biopharmaceutical executive Samit Hirawat, M.D., as a Class III director and member of the Science and Technology Committee, with the appointment announced publicly on January 28, 2026. The addition of Hirawat, an independent director with more than 25 years of clinical development and leadership experience at Bristol Myers Squibb and Novartis, underscores Pacira’s efforts to strengthen its governance and scientific oversight as it seeks to accelerate growth of its non-opioid pain portfolio and advance its pipeline, including next-generation gene therapies, potentially bolstering its competitive position in the non-opioid pain management market.

The most recent analyst rating on (PCRX) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.